Image-based metric of invasiveness predicts response to adjuvant temozolomide for primary glioblastoma.
Susan Christine MasseyHaylye WhitePaula WhitmireTatum DoyleSandra K JohnstonKyle W SingletonPamela R JacksonAndrea Hawkins-DaarudBernard R BendokAlyx B PorterSujay VoraJann N SarkariaLeland S HuMaciej M MrugalaKristin R SwansonPublished in: PloS one (2020)
Our finding that less diffusely invasive tumors are associated with greater volumetric response to TMZ suggests patients with these tumors may benefit from additional adjuvant TMZ cycles, even for those without MGMT methylation.